NASDAQ
4.40USD
-0.06 (-1.35%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
263.5M
P/E
—
EPS
—
Beta
0.50
52W range
2.2-5.424
Day range
4.27–4.65
Open
4.27
Prev close
4.46
Volume
344.5K
Avg volume
275.2K
Dividend
0.00
IPO
2020-08-04
https://www.zacks.com/stock/news/2972341/orchestra-biomed-holdings-inc-obio-reports-q2-loss-misses-revenue-estimates?cid=CS-STOCKNEWSAPI-FT-fundamental_analysis|yseop_template_4-2972341 · 8/10/2026-0.60
https://www.zacks.com/stock/news/2788914/orchestra-biomed-holdings-inc-obio-reports-q3-loss-beats-revenue-estimates?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|yseop_template_4-2788914 · 11/11/2025-0.30
https://www.globenewswire.com/news-release/2025/11/03/3179221/0/en/Orchestra-BioMed-to-Host-Business-Update-Call-on-November-12-2025.html · 11/3/2025+0.80
https://www.globenewswire.com/news-release/2025/10/09/3164075/0/en/Orchestra-BioMed-to-Showcase-Transformative-Potential-of-AVIM-Therapy-in-Keynote-Presentation-on-Hypertensive-Heart-Disease-at-Georgia-Innovation-Summit.html · 10/9/2025+0.80
https://www.zacks.com/stock/news/2703499/orchestra-biomed-holdings-inc-obio-reports-q2-loss-beats-revenue-estimates?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|yseop_template_4-2703499 · 8/12/2025+0.20
https://www.globenewswire.com/news-release/2025/08/12/3131673/0/en/Orchestra-BioMed-Reports-Second-Quarter-2025-Financial-Results-and-Highlights-Recent-Business-Updates.html · 8/12/2025+0.80
Orchestra BioMed Holdings, Inc. operates as an innovative company in the biomedical sector. Its leading product candidates are BackBeat Cardiac Neuromodulation Therapy (CNT), designed to manage hypertension, and the Virtue Sirolimus AngioInfusion Balloon (SAB), aimed at treating atherosclerotic artery disease. The company's offerings also encompass FreeHold retractors, which are solutions for minimally invasive surgical procedures. Orchestra BioMed has formed key alliances to advance its products: a strategic collaboration with Medtronic focuses on developing and commercializing BackBeat CNT for pacemaker-indicated patients suffering from hypertension. Additionally, a partnership with Terumo Corporation is dedicated to the development and market introduction of Virtue SAB for artery disease. The company's headquarters are located in New Hope, Pennsylvania.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
